Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland
Background and ObjectivesSince vaccination against COVID-19 is available for over a year and the population of immunized individuals with autoimmune disorders is higher than several months before, an evaluation of safety and registered adverse events can be made. We conducted a large study of side e...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.913283/full |
| _version_ | 1811258053047091200 |
|---|---|
| author | Agata Czarnowska Joanna Tarasiuk Olga Zajkowska Marcin Wnuk Monika Marona Klaudia Nowak Agnieszka Słowik Anna Jamroz-Wiśniewska Konrad Rejdak Beata Lech Małgorzata Popiel Iwona Rościszewska-Żukowska Adam Perenc Halina Bartosik-Psujek Mariola Świderek-Matysiak Małgorzata Siger Agnieszka Ciach Agata Walczak Anna Jurewicz Mariusz Stasiołek Karolina Kania Klara Dyczkowska Alicja Kalinowska-Łyszczarz Weronika Galus Anna Walawska-Hrycek Ewa Krzystanek Justyna Chojdak-Łukasiewicz Jakub Ubysz Anna Pokryszko-Dragan Katarzyna Kapica-Topczewska Monika Chorąży Marcin Bazylewicz Anna Mirończuk Joanna Kulikowska Jan Kochanowicz Marta Białek Małgorzata Stolarz Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Monika Adamczyk-Sowa Aleksandra Podlecka-Piçtowska Monika Nojszewska Beata Zakrzewska-Pniewska Elżbieta Jasińska Elżbieta Jasińska Jacek Zaborski Marta Milewska-Jȩdrzejczak Jacek Zwiernik Jacek Zwiernik Beata Zwiernik Beata Zwiernik Andrzej Potemkowski Waldemar Brola Alina Kułakowska |
| author_facet | Agata Czarnowska Joanna Tarasiuk Olga Zajkowska Marcin Wnuk Monika Marona Klaudia Nowak Agnieszka Słowik Anna Jamroz-Wiśniewska Konrad Rejdak Beata Lech Małgorzata Popiel Iwona Rościszewska-Żukowska Adam Perenc Halina Bartosik-Psujek Mariola Świderek-Matysiak Małgorzata Siger Agnieszka Ciach Agata Walczak Anna Jurewicz Mariusz Stasiołek Karolina Kania Klara Dyczkowska Alicja Kalinowska-Łyszczarz Weronika Galus Anna Walawska-Hrycek Ewa Krzystanek Justyna Chojdak-Łukasiewicz Jakub Ubysz Anna Pokryszko-Dragan Katarzyna Kapica-Topczewska Monika Chorąży Marcin Bazylewicz Anna Mirończuk Joanna Kulikowska Jan Kochanowicz Marta Białek Małgorzata Stolarz Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Monika Adamczyk-Sowa Aleksandra Podlecka-Piçtowska Monika Nojszewska Beata Zakrzewska-Pniewska Elżbieta Jasińska Elżbieta Jasińska Jacek Zaborski Marta Milewska-Jȩdrzejczak Jacek Zwiernik Jacek Zwiernik Beata Zwiernik Beata Zwiernik Andrzej Potemkowski Waldemar Brola Alina Kułakowska |
| author_sort | Agata Czarnowska |
| collection | DOAJ |
| description | Background and ObjectivesSince vaccination against COVID-19 is available for over a year and the population of immunized individuals with autoimmune disorders is higher than several months before, an evaluation of safety and registered adverse events can be made. We conducted a large study of side effects following the COVID-19 vaccine among patients with multiple (MS) sclerosis treated with disease-modifying therapies (DMTs) and analyzed factors predisposing for particular adverse events.MethodsWe gathered data of individuals with MS treated with DMTs from 19 Polish MS Centers, who reported at least one adverse event following COVID-19 vaccination. The information was obtained by neurologists using a questionnaire. The same questionnaire was used at all MS Centers. To assess the relevance of reported adverse events, we used Fisher's exact test, t-test, and U-Menn-Whutney test.ResultsA total of 1,668 patients with MS and reports of adverse events after COVID-19 vaccination were finally included in the study. Besides one case marked as “red flag”, all adverse events were classified as mild. Pain at the injection site was the most common adverse event, with a greater frequency after the first dose. Pain at the injection site was significantly more frequent after the first dose among individuals with a lower disability (EDSS ≤2). The reported adverse events following immunization did not differ over sex. According to age, pain at the injection site was more common among individuals between 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.ConclusionsAccording to our findings, vaccination against COVID-19 among patients with MS treated with DMTs is safe. Our study can contribute to reducing hesitancy toward vaccination among patients with MS. |
| first_indexed | 2024-04-12T18:07:21Z |
| format | Article |
| id | doaj.art-6e6c37368df744429fb87b66db39960f |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-12T18:07:21Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-6e6c37368df744429fb87b66db39960f2022-12-22T03:21:57ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-06-011310.3389/fneur.2022.913283913283Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in PolandAgata Czarnowska0Joanna Tarasiuk1Olga Zajkowska2Marcin Wnuk3Monika Marona4Klaudia Nowak5Agnieszka Słowik6Anna Jamroz-Wiśniewska7Konrad Rejdak8Beata Lech9Małgorzata Popiel10Iwona Rościszewska-Żukowska11Adam Perenc12Halina Bartosik-Psujek13Mariola Świderek-Matysiak14Małgorzata Siger15Agnieszka Ciach16Agata Walczak17Anna Jurewicz18Mariusz Stasiołek19Karolina Kania20Klara Dyczkowska21Alicja Kalinowska-Łyszczarz22Weronika Galus23Anna Walawska-Hrycek24Ewa Krzystanek25Justyna Chojdak-Łukasiewicz26Jakub Ubysz27Anna Pokryszko-Dragan28Katarzyna Kapica-Topczewska29Monika Chorąży30Marcin Bazylewicz31Anna Mirończuk32Joanna Kulikowska33Jan Kochanowicz34Marta Białek35Małgorzata Stolarz36Katarzyna Kubicka-Bączyk37Natalia Niedziela38Paweł Warmus39Monika Adamczyk-Sowa40Aleksandra Podlecka-Piçtowska41Monika Nojszewska42Beata Zakrzewska-Pniewska43Elżbieta Jasińska44Elżbieta Jasińska45Jacek Zaborski46Marta Milewska-Jȩdrzejczak47Jacek Zwiernik48Jacek Zwiernik49Beata Zwiernik50Beata Zwiernik51Andrzej Potemkowski52Waldemar Brola53Alina Kułakowska54Department of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandFaculty of Economic Sciences, University of Warsaw, Warsaw, PolandDepartment of Neurology, Jagiellonian University Medical College, Krakow, PolandDepartment of Neurology, Jagiellonian University Medical College, Krakow, PolandDepartment of Neurology, Jagiellonian University Medical College, Krakow, PolandDepartment of Neurology, Jagiellonian University Medical College, Krakow, PolandDepartment of Neurology, Medical University of Lublin, Lublin, PolandDepartment of Neurology, Medical University of Lublin, Lublin, PolandNeurology Clinic With Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Lwowska, PolandNeurology Clinic With Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Lwowska, PolandDepartment of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, PolandNeurology Clinic With Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Lwowska, PolandDepartment of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Medical University of Lodz, Łódz, PolandDepartment of Neurology, Poznan University of Medical Sciences, Poznań, PolandDepartment of Neurology, Poznan University of Medical Sciences, Poznań, PolandDivision of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznań, Poland0Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland0Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland0Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland1Department of Neurology, Wroclaw Medical University, Wroclaw, Poland1Department of Neurology, Wroclaw Medical University, Wroclaw, Poland1Department of Neurology, Wroclaw Medical University, Wroclaw, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandDepartment of Neurology, Medical University of Białystok, Białystok, Poland2Department of Neurology, Regional Specialised Hospital No. 4 in Bytom, Bytom, Poland2Department of Neurology, Regional Specialised Hospital No. 4 in Bytom, Bytom, Poland3Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland3Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland3Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland3Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland4Department of Neurology, Medical University of Warsaw, Warsaw, Poland4Department of Neurology, Medical University of Warsaw, Warsaw, Poland4Department of Neurology, Medical University of Warsaw, Warsaw, Poland5Jan Kochanowski University, Collegium Medicum, Kielce, Poland6Clinical Center, Resmedica, Kielce, Poland7Department of Neurology and Neurorehabilitation, Miedzyleski Szpital Specjalistyczny, Warsaw, Poland8Department of Neurology and Ischemic Strokes, Medical University of Lodz, Lodz, Poland9Neurology Ward, Provincial Specialist Hospital, Olsztyn, Poland0Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland1Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland2Clinic of Neurology, University of Warmia and Mazury, Olsztyn, Poland3Department of Clinical Psychology and Psychoprophylaxis, University of Szczecin, Szczecin, Poland4Department of Neurology, Specialist Hospital in Końskie, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, PolandDepartment of Neurology, Medical University of Białystok, Białystok, PolandBackground and ObjectivesSince vaccination against COVID-19 is available for over a year and the population of immunized individuals with autoimmune disorders is higher than several months before, an evaluation of safety and registered adverse events can be made. We conducted a large study of side effects following the COVID-19 vaccine among patients with multiple (MS) sclerosis treated with disease-modifying therapies (DMTs) and analyzed factors predisposing for particular adverse events.MethodsWe gathered data of individuals with MS treated with DMTs from 19 Polish MS Centers, who reported at least one adverse event following COVID-19 vaccination. The information was obtained by neurologists using a questionnaire. The same questionnaire was used at all MS Centers. To assess the relevance of reported adverse events, we used Fisher's exact test, t-test, and U-Menn-Whutney test.ResultsA total of 1,668 patients with MS and reports of adverse events after COVID-19 vaccination were finally included in the study. Besides one case marked as “red flag”, all adverse events were classified as mild. Pain at the injection site was the most common adverse event, with a greater frequency after the first dose. Pain at the injection site was significantly more frequent after the first dose among individuals with a lower disability (EDSS ≤2). The reported adverse events following immunization did not differ over sex. According to age, pain at the injection site was more common among individuals between 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.ConclusionsAccording to our findings, vaccination against COVID-19 among patients with MS treated with DMTs is safe. Our study can contribute to reducing hesitancy toward vaccination among patients with MS.https://www.frontiersin.org/articles/10.3389/fneur.2022.913283/fullmultiple sclerosisvaccinationSARS-CoV-2COVID-19side effects |
| spellingShingle | Agata Czarnowska Joanna Tarasiuk Olga Zajkowska Marcin Wnuk Monika Marona Klaudia Nowak Agnieszka Słowik Anna Jamroz-Wiśniewska Konrad Rejdak Beata Lech Małgorzata Popiel Iwona Rościszewska-Żukowska Adam Perenc Halina Bartosik-Psujek Mariola Świderek-Matysiak Małgorzata Siger Agnieszka Ciach Agata Walczak Anna Jurewicz Mariusz Stasiołek Karolina Kania Klara Dyczkowska Alicja Kalinowska-Łyszczarz Weronika Galus Anna Walawska-Hrycek Ewa Krzystanek Justyna Chojdak-Łukasiewicz Jakub Ubysz Anna Pokryszko-Dragan Katarzyna Kapica-Topczewska Monika Chorąży Marcin Bazylewicz Anna Mirończuk Joanna Kulikowska Jan Kochanowicz Marta Białek Małgorzata Stolarz Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Monika Adamczyk-Sowa Aleksandra Podlecka-Piçtowska Monika Nojszewska Beata Zakrzewska-Pniewska Elżbieta Jasińska Elżbieta Jasińska Jacek Zaborski Marta Milewska-Jȩdrzejczak Jacek Zwiernik Jacek Zwiernik Beata Zwiernik Beata Zwiernik Andrzej Potemkowski Waldemar Brola Alina Kułakowska Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland Frontiers in Neurology multiple sclerosis vaccination SARS-CoV-2 COVID-19 side effects |
| title | Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland |
| title_full | Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland |
| title_fullStr | Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland |
| title_full_unstemmed | Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland |
| title_short | Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland |
| title_sort | analysis of side effects following vaccination against covid 19 among individuals with multiple sclerosis treated with dmts in poland |
| topic | multiple sclerosis vaccination SARS-CoV-2 COVID-19 side effects |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.913283/full |
| work_keys_str_mv | AT agataczarnowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT joannatarasiuk analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT olgazajkowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT marcinwnuk analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT monikamarona analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT klaudianowak analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT agnieszkasłowik analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT annajamrozwisniewska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT konradrejdak analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT beatalech analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT małgorzatapopiel analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT iwonarosciszewskazukowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT adamperenc analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT halinabartosikpsujek analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT mariolaswiderekmatysiak analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT małgorzatasiger analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT agnieszkaciach analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT agatawalczak analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT annajurewicz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT mariuszstasiołek analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT karolinakania analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT klaradyczkowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT alicjakalinowskałyszczarz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT weronikagalus analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT annawalawskahrycek analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT ewakrzystanek analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT justynachojdakłukasiewicz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT jakububysz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT annapokryszkodragan analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT katarzynakapicatopczewska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT monikachorazy analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT marcinbazylewicz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT annamironczuk analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT joannakulikowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT jankochanowicz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT martabiałek analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT małgorzatastolarz analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT katarzynakubickabaczyk analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT natalianiedziela analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT pawełwarmus analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT monikaadamczyksowa analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT aleksandrapodleckapictowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT monikanojszewska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT beatazakrzewskapniewska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT elzbietajasinska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT elzbietajasinska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT jacekzaborski analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT martamilewskajedrzejczak analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT jacekzwiernik analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT jacekzwiernik analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT beatazwiernik analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT beatazwiernik analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT andrzejpotemkowski analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT waldemarbrola analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland AT alinakułakowska analysisofsideeffectsfollowingvaccinationagainstcovid19amongindividualswithmultiplesclerosistreatedwithdmtsinpoland |